Tarsus Pharmaceuticals, Inc. 近日披露了其针对莱姆病的主要在研疫苗项目的最新进展。根据公司规划，该候选疫苗的患者招募工作预计将在2026年蜱虫活跃季节全面完成。
这一关键时间点的设定，与莱姆病传播的高峰期相吻合，旨在确保临床试验能够充分评估疫苗在真实环境下的保护效力。紧随招募完成之后，研究团队将进入密集的数据收集与统计分析阶段。
公司明确表示，该项目的重要顶线结果预计将于2027年上半年对外公布。这一结果将首次揭示该疫苗在关键有效性终点上的表现，备受市场关注。
若数据积极，将为后续向监管机构提交申请奠定坚实基础，并有望填补当前莱姆病预防领域存在的重大未满足医疗需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.